Atorvastatin Cyclic Fluorophenyl Impurity(Potassium Salt)
✓
100% accuracy
of data
24/7 scientific
support
⬡
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

Atorvastatin Cyclic Fluorophenyl Impurity(Potassium Salt)

● In Stock

Catalogue No.:VE0026800
CAS No.:N/A
Mol. Formula:C33H34FKN2O7
Mol. Weight:628.73 g/mol

Additional information on

Parent drug

Atorvastatin

IUPAC Name

potassium (3R)-4-[1-(4-fluorophenyl)-5-hydroxy-2-phenyl-4-(phenylcarbamoyl)-5-propan-2-yl-3,10-dioxa-6-azatricyclo[4.4.0.02,4]decan-9-yl]-3-hydroxybutanoate

Smiles

CC(C1([O])C2(C(NC3=CC=CC=C3)=[OH])C(C4(C5=CC=CC=C5)N1CCC(C[C@@H](O)CC([O-])=O)O4)(C6=CC(F)=CC=C6)O2)C.[K+]

InChI

InChI=1S/C33H35FN2O7.K/c1-21(2)32(41)31(29(40)35-25-14-7-4-8-15-25)30(43-31,23-12-9-13-24(34)18-23)33(22-10-5-3-6-11-22)36(32)17-16-27(42-33)19-26(37)20-28(38)39;/h3-15,18,21,26-27,35,37,40H,16-17,19-20H2,1-2H3,(H,38,39);/q;+1/p-1/t26-,27?,30?,31?,32?,33?;/m1./s1

Description

Atorvastatin Cyclic Fluorophenyl Impurity (Potassium Salt) is a process- and degradation-related impurity observed during atorvastatin API synthesis and storage. This non-parental cyclic fluorophenyl species can arise from intramolecular cyclization under acidic or high-temperature conditions and may persist as a potassium counterion salt. Characterization relies on orthogonal analytical techniques including reversed-phase HPLC for quantitation, LC-MS for molecular confirmation, 1H and 19F NMR for structural elucidation, and elemental analysis for counterion verification. Control strategies focus on precursor purity, optimized reaction conditions, and targeted purification steps to meet specification limits. Understanding formation pathways and robust analytical methods supports regulatory compliance and product quality.

Request a Quote

« * » indique les champs nécessaires

Ce champ n’est utilisé qu’à des fins de validation et devrait rester inchangé.
Products quotation
Name
Url